PO-0753: Phase I trial evaluating MEK inhibitor selumetinib with concomitant thoracic radiotherapy in NSCLC. (April 2018) - Haslett, K.; Blackhall, F.; Koh, P.; Ashcroft, L.; Asselin, M.; Harris, C.; Jackson, A.; Manoharan, P.; Mullan, D.; Ryder, W.; Taylor, B.; Faivre-Finn, C.